Fitness Cost of VanA-Type Vancomycin Resistance in Methicillin-Resistant Staphylococcus aureus
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We have quantified the biological cost of VanA-type glycopeptide resistance due to the acquisition of the resistance operon by methicillin-resistant Staphylococcus aureus (MRSA) from Enterococcus sp. Exponential growths of recipient strain HIP11713, its transconjugant VRSA-1, VRSA-5, and VRSA-6 were compared in the absence or, except for HIP11713, in the presence of vancomycin. Induction of resistance was performed by adding vancomycin in both the preculture and the culture or the culture at only 1/50 the MIC. In the absence of vancomycin, the growth rates of the vancomycin-resistant S. aureus (VRSA) strains were similar to that of susceptible MRSA strain HIP11713. When resistance was induced, and under both conditions, there was a significant reduction of the growth rate of the VRSA strains relative to that of HIP11713 and to those of their noninduced counterparts, corresponding to a ca. 20% to 38% reduction in fitness. Competition experiments between isogenic VRSA-1 and HIP11713 mixed at a 1:1, 1:100, or 100:1 ratio revealed a competitive disadvantage of 0.4% to 3% per 10 generations of the transconjugant versus the recipient. This slight fitness burden can be attributed to the basal level of expression of the van genes in the absence of induction combined with a gene dosage effect due to the presence of the van operon on multicopy plasmids. These data indicate that VanA-type resistance, when induced, is highly costly for the MRSA host, whereas in the absence of induction, its biological cost is minimal. Thus, the potential for the dissemination of VRSA clinical isolates should not be underestimated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arthur, M., Molinas, C., & Courvalin, P. (1992) · Journal of Bacteriology · doi:10.1128/jb.174.8.2582-2591.1992 · Cited by 338
Self-citation
Cited by
Antibiotic resistance and its cost: is it possible to reverse resistance?
Andersson, D. I., & Hughes, D. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2319 · Cited by 2,294
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Methicillin-resistant Staphylococcus aureus
Lee, A. S., de Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A., & Harbarth, S. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.33 · Cited by 1,556
Beceiro, A., Tomás, M., & Bou, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-12 · Cited by 1,070
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
“the genetics of resistance have not been verified in a second laboratory in these cases (3, 84, 247, 292, 323).”
BackgroundIntrinsic and acquired resistance mechanisms in enterococcus
Hollenbeck, B. L., & Rice, L. B. (2012) · Virulence · doi:10.4161/viru.21282 · Cited by 795
Multidrug evolutionary strategies to reverse antibiotic resistance
Baym, M., Stone, L. K., & Kishony, R. (2016) · Science · doi:10.1126/science.aad3292 · Cited by 710
Vancomycin resistance in Staphylococcus aureus
Appelbaum, P. C., & Bozdogan, B. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.03.004 · Cited by 485
The genetic basis of the fitness costs of antimicrobial resistance: a meta‐analysis approach
Vogwill, T., & MacLean, R. C. (2015) · Evolutionary Applications · doi:10.1111/eva.12202 · Cited by 443
Persistence of antibiotic resistance in bacterial populations
Andersson, D. I., & Hughes, D. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00289.x · Cited by 435
VanA-Type Vancomycin-Resistant Staphylococcus aureus
Périchon, B., & Courvalin, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00346-09 · Cited by 334
Self-citationGenomic variation and evolution of Staphylococcus aureus
Lindsay, J. A. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2009.08.013 · Cited by 274
Multi-drug-resistant Staphylococcus aureus and future chemotherapy
Hiramatsu, K., Katayama, Y., Matsuo, M., Sasaki, T., Morimoto, Y., Sekiguchi, A., & Baba, T. (2014) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2014.08.001 · Cited by 243
Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?
Cattoir, V., & Leclercq, R. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks469 · Cited by 234
Harro, C., Betts, R., Orenstein, W., Kwak, E.-J., Greenberg, H. E., Onorato, M. T., Hartzel, J., Lipka, J., DiNubile, M. J., & Kartsonis, N. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00356-10 · Cited by 57
“aureus has emerged as a real threat, especially when associated with decreased susceptibility to vancomycin (1, 2, 4, 6, 7, 9, 14, 20, 28, 38, 41).”
Background
Metadata
- Authors
- Foucault, M.-L., Courvalin, P., & Grillot-Courvalin, C.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-06
- Volume
- 53
- Issue
- 6
- Pages
- 2354-2359
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2144912604
- Cited by
- 137
- References
- 1
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.